sub:assertion {
  d:DB00764 v:identifier "DB00764" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB00764" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB00764> ;
    dv:drugbank-id "APRD00289" , "DB00764" ;
    dv:x-ahfs <http://bio2rdf.org/ahfs:52:08.08> ;
    dv:x-atc <http://bio2rdf.org/atc:D07AC13> ;
    dv:x-cas <http://bio2rdf.org/cas:105102-22-5> ;
    dv:x-chebi <http://bio2rdf.org/chebi:6970> ;
    dv:x-dpd <http://bio2rdf.org/dpd:2244769> ;
    dv:x-kegg <http://bio2rdf.org/kegg:C07816> ;
    dv:x-ndc <http://bio2rdf.org/ndc:0085-0370-01> ;
    dv:x-pdb <http://bio2rdf.org/pdb:MOF> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA450541> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Mometasone> ;
    dct:description "Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. he antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes."@en ;
    dct:identifier "drugbank:DB00764" ;
    dct:title "Mometasone"@en ;
    a dv:Drug ;
    rdfs:label "Mometasone [drugbank:DB00764]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB00764> , <http://www.drugs.com/cdi/mometasone-spray.html> , <http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/nas1518.shtml> , <http://www.rxlist.com/cgi/generic2/momet1.htm> .
}